Co-Authors
This is a "connection" page, showing publications co-authored by Ming-Hua Zheng and Yong-Ping Chen.
Connection Strength
4.303
-
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Front Endocrinol (Lausanne). 2021; 12:604100.
Score: 0.233
-
Radiomics-based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) and influenza A infected pneumonia. MedComm (2020). 2020 Aug 13.
Score: 0.224
-
Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020 09; 40(9):2160-2163.
Score: 0.223
-
A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. J Gen Intern Med. 2020 07; 35(7):2205-2206.
Score: 0.223
-
Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021 Jan; 36(1):204-207.
Score: 0.221
-
Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab. 2020 11; 46(6):505-507.
Score: 0.221
-
Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. Nephron. 2020; 144(7):347-350.
Score: 0.221
-
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 08; 69(8):1545-1547.
Score: 0.221
-
Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care. 2020 Jul; 43(7):e72-e74.
Score: 0.220
-
Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020 09; 46(4):335-337.
Score: 0.220
-
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020 09; 73(3):719-721.
Score: 0.220
-
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020 07; 108:154244.
Score: 0.219
-
Serum lactate level accurately predicts mortality in critically ill patients with cirrhosis with acute kidney injury. Eur J Gastroenterol Hepatol. 2018 11; 30(11):1361-1367.
Score: 0.198
-
Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis. Eur J Gastroenterol Hepatol. 2018 07; 30(7):747-755.
Score: 0.194
-
High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier. Cell Immunol. 2018 06; 328:24-32.
Score: 0.190
-
Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018 04; 2(4):376-392.
Score: 0.189
-
Stratified alpha-fetoprotein pattern accurately predicts mortality in patients with acute-on-chronic hepatitis B liver failure. Expert Rev Gastroenterol Hepatol. 2018 Mar; 12(3):295-302.
Score: 0.188
-
BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. Mol Immunol. 2018 01; 93:38-46.
Score: 0.185
-
Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway. Immunol Lett. 2017 10; 190:169-176.
Score: 0.182
-
Quick chronic liver failure-sequential organ failure assessment: an easy-to-use scoring model for predicting mortality risk in critically ill cirrhosis patients. Eur J Gastroenterol Hepatol. 2017 Jun; 29(6):698-705.
Score: 0.180
-
Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int. 2013 Jan; 33(1):62-71.
Score: 0.130